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Two genetic variants of the bovine β-casein gene (A1 and B) encode a histidine residue 
at codon 67, resulting in potential liberation of a bioactive peptide, β-casomorphin, 
upon digestion. An allele-specific PCR (AS-PCR) was evaluated to distinguish between 
the β-casomorphin-releasing variants (A1 and B) and the non-releasing variants. AS-
PCR successfully distinguished β-casein variants in 41 of 42 animals as confirmed by 
sequence analysis. Overall, while the incidence of the homozygous A1 and B animals 
(i.e., homozygous for the histidine residue; 21.4%) was lower than that for animals 
without the histidine residue (30.9% respectively), 69% of animals carried at least one 
allele for the histidine residue at codon 67.
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Introduction
Milk protein has the potential to yield 
opioid-like peptides following proteolysis. 
These peptides have been termed “food 
hormones” and have been reported to elicit 
their bioactive effects when released from 
food constituents (Teschemacher, 2003). 
The major exogenous milk protein-derived 
opioid peptides are the β-casomorphins, 
which are liberated upon digestion of cer-
tain variants of β-casein, namely the A1 and 
B variants (Svenberg et al., 1985; Meisel, 
1986). The β-casein gene has 12 known 
genetic variants in the coding sequence 
of the gene (Farrell et al., 2004). Genetic 
variants A1, A2, A3 and B are universally 
distributed in almost all Bos taurus and 
Bos indicus populations. The base chang-
es encoding the amino acid differences 
between these four variants are located in 
exon VII that encodes the major part of the 
mature protein (Bonsing et al., 1988). The 
β-casein A1 and B variants differ from the 
A2 variant at position 67 where a histidine 
replaces a proline. In addition, the B vari-
ant differs from the A1 variant in a substitu-
tion of arginine for serine at position 122. 
(Other variants – C, F & G – also have a his-
tidine residue at position 67). Importantly, 
it is the change to histidine at position 67 
that has the potential to result in cleav-
age occurring upon digestion and a bioac-
tive peptide, beta-casomorphin potentially 
being liberated (Lien et al., 1992; Stewart 
et al., 1987; Damiani et al., 1992). 
Consumption of the A1 and B protein 
variants of bovine β-casein has been impli-
cated in the development of diabetes and 
coronary heart disease (CHD). It has also 
been shown that β-casein protein from 
animals with the position 67 base change 
(A1 or B allele) induced diabetes in NOD 
mice (Elliott et al., 1988). Elliott et al. 
(1999) compared the incidence of Type 1 
diabetes in 0 to 14 year-old children from 
10 different countries with the national 
consumption of protein from cows’ milk. 
While total protein consumption was not 
correlated with diabetes incidence (r = 
0.40), the consumption of the β-casein A1 
variant was associated with the incidence 
of diabetes (r = 0.73). There was an even 
closer relationship between the combined 
consumption of A1 and B variants and dia-
betes (r = 0.98; Elliott et al., 1999). 
It has been hypothesised that consump-
tion of the β-casein A1 and B protein 
variants are a specific risk factor for the 
development of CHD based on a study 
using data measured for dairy breeds 
in several countries (McLachlan, 2001). 
Results for France vs. Northern Ireland 
were particularly striking where disease 
mortality in middle-aged men was shown 
to be between three and four times higher 
in Belfast than in Toulouse, as was their 
consumption of the β-casein A1 and B 
protein variants. Cardiovascular disease 
is one of the biggest killers in Ireland: it 
accounts for 42% of all deaths – the high-
est of any European country and twice 
the EU average. Ireland has also been 
reported to have a high incidence of Type 
1 diabetes within Europe (Roche et al., 
2002). In recent years human consump-
tion of β-casein A1 and B protein variants 
has been brought to the public’s attention, 
in particular in New Zealand, where A2 
milk is marketed by the A2 Corporation 
as being a lower risk factor for disease 
development. 
In this study we investigated the cytosine 
to adenine base change which results in the 
amino acid change at position 67 and the 
potential release of a bioactive peptide. The 
A1 and B variants (and others with the histi-
dine residue at position 67) were therefore 
combined and referred to as A1 throughout, 
while other variants are referred to herein 
as A2. Allele-specific primers were evaluat-
ed for their use in assessing the presence of 
the A1 base change. In addition, a number 
of genetically unrelated (non-dairy) animals 
were studied. 
Materials and Methods
Blood sampling and DNA extraction
Approximately 15 ml of blood was col-
lected into heparinised tubes from the 
coccygeal vein of 42 cattle representing 10 
breeds. Breeds involved were high genet-
ic merit Holstein-Friesian, low genetic 
merit Holstein-Friesian, Irish-Friesian, 
Dutch-Friesian, Limousin, Montbeliarde, 
Charolais, Normande, Norwegian Red and 
Kerry. With the exception of the Limousin, 
Charolais and Kerry animals, these sub-
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jects were part of the herd at Teagasc, 
Moorepark, Fermoy, Co. Cork. Limousin 
and Charolais samples were from Teagasc, 
Grange, Co. Meath, while Kerry samples 
were obtained from the herd at Muckross 
House, Killarney, Co. Kerry. DNA extrac-
tion was carried out using the Gentra 
Capture Column™ (Gentra, Minneapolis, 
MN55441, USA) system for approximate-
ly 200 µl of whole blood per animal. Blood 
was stored at –80 oC and DNA was stored 
at –20 oC until further use. 
Primer design and polymerase chain  
reaction (PCR)
Allele-specific PCR was carried out using 
a common forward primer (Bwtp3; 5′-
GCCCAGATGAGAGAAGTGAGG-3′), 
and reverse primers with either T or G at 
the 3' end (5′-GATGTTTTGTGGGAGGC- 
TGTTAT/G-3′) to amplify an 854 bp frag-
ment (Figure 1a). The polymorphisms rep-
resented by the A3 variant and the sec-
ond polymorphism (codon 122) associated 
with the B variant were not present in this 
Figure 1. Comparison of allele-specific PCR results and sequencing validation. (a) Primer 
design and layout. (b) Sequencing chromatograms representing each of the three genotypes 
(A1A1, A1A2, A2A2). (c) Three animals (genotype in parenthesis) are shown as examples 
of typical results. Lane 1: Marker (M). Lane 2, 4, 6: A1-specific primer PCR. Lane 3, 5, 7: 
A2-specific primer PCR.
amplicon and therefore could not inter-
fere with the interpretation of the results. 
Additional primers were used to ampli-
fy a 730 bp fragment encompassing the 
polymorphism for sequence validation 
(5 ′-GGCCATTGTTAAGGAACTCC-
3′;5′-AAGGTGCAGATTTTCAACAT-3′). 
Primers were synthesised by MWG Biotech 
(90 Long Acre, Covent Garden, London, 
WC2E 9RZ). PCR was carried out from a 
starting template of approximately 200 ng of 
genomic DNA in a final volume of 50 µl con- 
taining 1X Taq DNA polymerase buffer (Invi- 
trogen Ltd, 3 Fountain Drive, Inchinnan Bus- 
iness Park, Paisley, UK, PA49RF), 1.5 mM 
MgCl2, 200 µM dNTPs (Promega), 0.3 µM 
of each primer and 1U Taq polymerase 
(Invitrogen). After an initial incubation at 
95 oC for 2 min, samples were amplified for 
30 cycles at 95 oC for 1 min, 58 oC for 1 min 
and 72 oC for 1 min. PCR product sequenc-
ing was carried out by MWG Biotech. The 
resulting sequences were analysed using the 
Vector NTI® suite of software (Invitrogen). 
Results 
An examination of the electrophoretic 
analyses for the animals predicted their 
genotype through the use of AS-PCR 
(Figure 1), and these results are listed in 
Table 1 for each of the 42 animals. These 
PCR products were sequenced and their 
genotype determined. With the exception 
of one animal, as indicated, the results 
matched perfectly. Use of the AS-PCR 
method distinguished the A1 from A2 base 
change with a success rate of 97%. Results 
of the investigation (combining AS-PCR 
and sequencing data) were as follows: 
A1A1 – 21.4%, A2A2 – 30.9%, A1A2 – 47.6%. 
Overall the incidence of A1 allele carri- 
ers (either one or two copies of A1 allele) 
was 69%. 
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Table 1. Genotypes of animals determined by AS-PCR and sequence analysis
Dairy breeds Dual purpose breeds Beef breeds
Animal Genotype Animal Genotype Animal Genotype
0011 A1A2 0163 A1A1 0292 A2A2
0026 A1A2 0166 A1A1 191C A1A2
3048 A1A2 1226 A1A1 0183 A2A2
9615 A2A2 1267 A1A2 0094 A2A2
0050 A1A2 1212 A1A1 42L A1A2
0059 A1A2  0130* A1A2 215W A1A2
0081 A2A2 1023 A1A2 0069 A2A2
0876 A1A1 1545 A1A1 0086 A1A2
0599 A1A2 39 A2A2
1668 A1A2 40 A2A2
1270 A2A2 41 A1A2
1257 A1A2 42 A1A2
0407 A1A2 43 A2A2
0287 A1A1 44 A2A2
0188 A1A1 45 A1A2
0508 A1A2 46 A2A2
1535 A1A1
0191 A2A2
* Sample that was incorrectly identified by AS-PCR. 
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Discussion
The incidence of the A1 variant of β-casein 
has been the focus of much interest in the 
last decade due to the possibility that a 
bioactive peptide is liberated from these 
variants upon enzymatic digestion. While 
evidence for a clear link between this 
bioactive peptide and a disease state has 
not been demonstrated, it is desirable to 
have some indication of the incidence 
of this genetic variant in the Irish herd. 
Neither the base change encoding these 
variants nor the “wild-type” leads to any 
recognition site for a restriction enzyme, 
ruling out the use of restriction fragment 
length polymorphisms (RFLP) to distin-
guish between the variants. Therefore, the 
use of allele-specific primers, with a single 
base change (T/G) at the 3' end comple-
mentary to the base change of the spe-
cific β-casein variant (A1, B primer – T, A2 
primer – G) was evaluated. Allele-specific 
PCR uses two allelic-specific primer sets 
differing from each other in their 3' ter-
minal nucleotide and was first described 
by Wu et al. (1989). A single band of 854 
bp should only result for one or other of 
the allele-specific (AS) reactions if the 
template is homozygous or a band should 
appear with both allele-specific reactions 
in the case of a heterozygous template. 
Genotypes were predicted for each ani-
mal using the AS-PCR method. A further 
PCR was used to amplify a 730 bp frag-
ment spanning the polymorphic site. The 
predicted genotypes from AS-PCR was 
incorrect in the case of one animal. Some 
further optimisation of the amplification 
conditions may be appropriate to ensure 
a 100% success rate. Regardless, we feel 
that the use of these allele-specific prim-
ers successfully distinguished between the 
genetic variants. 
When the different bovine breeds were 
examined and divided into dairy (Holstein 
Friesian (high or low genetic merit), Irish 
Friesian, Norwegian Red, Dutch Friesian), 
dual-purpose (Normande, Montbeliarde, 
Kerry) and beef (Charolais, Limousin) 
animals, it was observed that the high-
est incidence of the β-casein A1 (or B) 
allele occurred in the dairy breeds (77%), 
compared with the dual-purpose (69%). 
The beef breeds had a lower incidence 
(50%). This study, however, involved a 
small number of animals and thus may 
not be indicative of the overall incidence 
in the Irish cow herd. Examination of a 
larger sample of the Irish national dairy 
herd may therefore be desirable to obtain 
a more precise estimate of the incidence 
of the β-casein A1 and B variants, for 
example using either milk or semen sam-
ples. Removal of this genotype from the 
national herd might prove beneficial for 
both the health and dairy industries; how-
ever the consequences of removal of this 
milk protein variant should first be care-
fully considered. 
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